Details of the Drug Combination

General Information of Drug Combination (ID: DC98LUG)

Drug Combination Name
Acarbose Exenatide
Indication
Disease Entry Status REF
Hyperinsulinemic Hypoglycemia Phase 1 [1]
Component Drugs Acarbose   DMRM3AW Exenatide   DMYHBKN
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL is unavailable

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Acarbose
Disease Entry ICD 11 Status REF
Diabetic complication 5A2Y Approved [2]
Non-insulin dependent diabetes 5A11 Approved [3]
Cardiovascular disease BA00-BE2Z Phase 3 [2]
Acarbose Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Intestinal maltase-glucoamylase (MGAM) TTXWASR MGA_HUMAN Modulator [7]
------------------------------------------------------------------------------------
Indication(s) of Exenatide
Disease Entry ICD 11 Status REF
Inflammation 1A00-CA43.1 Approved [4]
Non-insulin dependent diabetes 5A11 Approved [4]
Type-1/2 diabetes 5A10-5A11 Approved [4]
Type-2 diabetes 5A11 Approved [5]
Cardiovascular disease BA00-BE2Z Phase 3 [6]
Exenatide Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Glucagon-like peptide 1 receptor (GLP1R) TTVIMDE GLP1R_HUMAN Binder [8]
------------------------------------------------------------------------------------
Exenatide Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Dipeptidyl peptidase IV (DPP4) DEKZQY6 DPP4_HUMAN Metabolism [9]
------------------------------------------------------------------------------------
Exenatide Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Albumin (ALB) OTVMM513 ALBU_HUMAN Affects Binding [10]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT02685852) Evaluating Exenatide for the Treatment of Postprandial Hyperinsulinemic Hypoglycemia
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6791).
3 Acarbose FDA Label
4 Exenatide FDA Label
5 Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
8 Improved glycemic control and reduction of cardiometabolic risk factors in subjects with type 2 diabetes and metabolic syndrome treated with exenatide in a clinical practice setting. Diabetes TechnolTher. 2009 Jun;11(6):353-9.
9 In vitro metabolic stability of exendin-4: pharmacokinetics and identification of cleavage products. PLoS One. 2015 Feb 27;10(2):e0116805.
10 Biochemical, pharmaceutical and therapeutic properties of long-acting lithocholic acid derivatized exendin-4 analogs. J Control Release. 2010 Mar 3;142(2):206-13. doi: 10.1016/j.jconrel.2009.10.025. Epub 2009 Nov 10.